Daily close, T-120 (11/12/24) through T+5. Run-up high $216.66 on 3/11/25, low $164.99 on 11/26/24 (T-120 to T-1). FDA decision 4/29/25. Historical price action, not a forecast.
Positioning before the decision
On Apr 15, 2025, 14 days before the decision date, at-the-money options priced a move of ±6.5% through May 2, 2025 (the first listed expiry after the decision; ATM implied volatility 38%). The stock closed +0.6% at the first close across the decision and +1.9% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Upadacitinib (RINVOQ) - (SELECT-GCA) approved by the FDA?
Yes. The FDA approved the application for Upadacitinib (RINVOQ) - (SELECT-GCA) on April 29, 2025. The primary source is linked on this page.
What was Upadacitinib (RINVOQ) - (SELECT-GCA) under FDA review for?
The application covered Giant cell arteritis (GCA). The FDA approved the application on April 29, 2025.
How did ABBV stock react to the FDA decision?
On the decision day ABBV moved +0.6%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.